FEMOM

Fetal heart rate monitoring (FHR) using cardiotocography (CTG) remains the most commonly used test in pregnancy in ensuring fetal well-being. However, it has several limitations such as being poor at detecting fetal compromise, being an inpatient test and requiring clinician oversight. To improve these, FEMOM, a wearable ambulatory device, has been invented to enable prescribed woman centric clinical grade FHR monitoring from home. This uses a state of the art monitoring technology called the non-invasive fetal electrocardiogram (NIFECG) which provides more clarity on how the fetus heart is functioning in contrast to routine CTG. This work aims to investigate how intensive monitoring of high-risk pregnancies, particularly those with fetal growth restriction, can aid in avoiding the devastating outcome of stillbirth. Also, it aims to redefine how pregnancy monitoring is carried out as a whole so it can be more lifestyle friendly to the 20th century woman and place more control into their hands.